Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CFO Sandip Kapadia sold 354 shares of Intercept Pharmaceuticals stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $58.83, for a total value of $20,825.82. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded up 4.52% during midday trading on Wednesday, hitting $68.73. The stock had a trading volume of 1,847,081 shares. The stock has a 50 day moving average price of $94.11 and a 200-day moving average price of $111.08. Intercept Pharmaceuticals, Inc. has a 52 week low of $54.98 and a 52 week high of $156.65. The stock’s market capitalization is $1.73 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The business’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same period last year, the company earned ($3.14) EPS. Equities research analysts anticipate that Intercept Pharmaceuticals, Inc. will post ($13.99) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) CFO Sells $20,825.82 in Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/04/intercept-pharmaceuticals-inc-icpt-cfo-sells-20825-82-in-stock.html.

Several brokerages have weighed in on ICPT. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday. JMP Securities downgraded Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Credit Suisse Group reaffirmed an “outperform” rating and set a $201.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $135.00 target price (down previously from $275.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $162.88.

Hedge funds have recently bought and sold shares of the company. WFG Advisors LP lifted its stake in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 125 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 132 shares during the period. US Bancorp DE acquired a new position in shares of Intercept Pharmaceuticals in the 1st quarter valued at $130,000. IFP Advisors Inc lifted its stake in shares of Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 730 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Intercept Pharmaceuticals in the 1st quarter valued at $170,000. 82.19% of the stock is currently owned by institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.